Clinical Trial Search

Primary: Median Percent Change From Baseline in All Partial Seizure Frequency (Complex Partial Seizures (CP)+ Simple Partial Seizures (SP) + Secondary Generalization Seizures…

Primary: Reversal Time of Rocuronium — 124.9; 171.1 seconds

Primary: Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 16 — 15.9; 28.0; 30.7 percentage of participants — p=0.0062

Primary: Progression-Free Survival (PFS) as Assessed by the Investigator — 10.2; 8.8 Months

Primary: Brain-derived Neurotrophic Factor (BDNF) DNA Methylation of Major Depressive Disorder (MDD) Patients and Healthy Controls — 92; 92; 75; 75 percent — p=<0.05

Primary: Phase I: Absolute Lens Rotation — 6.73; 11.38 Degrees

Primary: Change During Darusentan Treatment in the Markovian Homogeneity Number, a Value That Quantitates Myocardial Perfusion Heterogeneity — 0.33; 0.39 No units

Primary: Time to Progression of Disease — 12.6; 9.9 Months — p=0.196

Primary: Change From Baseline in Total Nasal Symptom Score (TNSS) Assessed by the Investigator at Week 2 — -1.96; -1.94; -1.87 Score on a Scale — p=0.661

Primary: Adherence to Initial Follow-up (Yes/no) — 60; 54; 58 percentage of patients who were adherent

Primary: Stem Survivorship (%) — 94.64 stem survivorship percentage at 5 years — p=0.0136

Primary: Plasma Glucose iAUC (Incremental Area Under the Curve; mM*Min) — 836; 693 glucose iAUC (mM*min) — p=0.003

Primary: Number of Participants With Seroconversion to Vaccine Antigens Following Vaccination With JE-CV by GPO MBP Lots — 0; 0; 0; 0 Participants

Primary: Speech Perception With Control and Experimental Conditions Both Tested in Quiet, in Speech-spectrum Noise, and in Multi-talker Babble Noise. — 0.2; 88.3; 88.5; 2.8…

Primary: Clinical Evidence of Complete Clearance of the Treatment-targeted Great Toenail Plus a Negative Fungal Culture at Day 360 — 2; 27 participants